← Back to screener

Benitec Biopharma Inc. BNTC

Rank #2253 · Nasdaq · $0.3B market cap
Audited by Baker Tilly US, LLP, no going-concern flag in the latest filing.
Score
27.2
P/E
-7.9
P/B
6.35
ROE
-80.3%
Op. Margin
–%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -7.9x, P/B 6.35x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -80.3%. Ranks in the top 93% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$0.0B$0.0B$0.0B21.219
2021$0.0B$-0.0B$-0.0B$0.0B-8118.68
2022$0.0B$-0.0B$-0.0B$0.0B-23044.113
2023$0.0B$-0.0B$-0.0B$0.0B-24457.515
2024$0.0B$-0.0B$-0.0B$0.0B-25441.3148
2025–$-0.0B$-0.0B$0.0B–2456
2026–$-0.0B$-0.0B$0.0B–5

← See the full screener